Introduction {#Sec1}
============

Hypoactivity of *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptors has been identified as a possible mechanism underlying pathological symptoms and cognitive deficits in schizophrenia (Goff and Coyle [@CR19]). Agents that enhance NMDA activity have produced mixed results in schizophrenia, with improvement of negative symptoms in some but not all trials (Buchanan et al. [@CR11]; Tuominen et al. [@CR38]) and largely negative effects on measures of learning and memory (Buchanan et al. [@CR11]; Goff et al. [@CR20], [@CR21]). Animal studies have demonstrated that tolerance rapidly develops for the cognitive-enhancing effects of the glycine site partial agonist, [d]{.smallcaps}-cycloserine, following repeated dosing (Parnas et al. [@CR27]; Quartermain et al. [@CR33]), possibly reflecting the trafficking of NMDA receptors from cell membrane to the intracellular compartment in response to increased activity at the glycine site (Nong et al. [@CR26]).

Targeting pharmacological treatments at points "downstream" from the NMDA receptor, at the level of intracellular biochemical pathways, represents an alternative strategy to avoid the development of tolerance. Activation of NMDA receptors results in calcium influx into the cell, which binds to calmodulin and activates neuronal nitric oxide (NO) synthase (NOS), thereby increasing intracellular NO concentrations. NO activates guanylyl cyclase, which increases cyclic guanine monphosphate (cGMP; Fig. [1](#Fig1){ref-type="fig"}). This "NMDA--NO--cGMP intracellular pathway" is believed to mediate long-term potentiation and memory consolidation (Erceg et al. [@CR18]; Prickaerts et al. [@CR29]; Yamada et al. [@CR42]). Phosphodiesterase 5 (PDE5) inhibitors act to increase cGMP without directly affecting NMDA receptors. Targeting PDE5 to increase cGMP might selectively correct deficits resulting from NMDA receptor hypofunction without the development of tachyphylaxis. Fig. 1Phosphodiesterase 5 (*PDE5*) inhibitors are believed to enhance memory and learning via facilitation of long-term potentiation (*LTP*) mediated by the "glutamate--nitric oxide--cyclic GMP intracellular pathway." Glutamate binding to the *N*-methyl-[d]{.smallcaps}-aspartate (*NMDA*) receptor results in calcium (*Ca*^*2+*^) influx, which binds to calmodulin and activates nitric oxide synthase (*NOS*). NOS catalyzes the production of nitric oxide (*NO*) from arginine; NO activates guanylyl cyclase, which increases production of cyclic guanosine monophosphate (*GMP*) from guanosine triphosphate (*GTP*). Cyclic GMP mediates LTP and activates protein kinases (*PK*), which are believed to mediate memory consolidation via phosphorylation and protein formation. PDE5 inhibitors block the conversion of cGMP to 5′GMP; by elevating cGMP levels, LTP is facilitated

Three PDE5 inhibitors are currently approved for the treatment of erectile dysfunction (sildenafil, tadalafil, and vardenafil; Rosen and Kostis [@CR34]). These agents readily cross the blood--brain barrier, are very well tolerated, and recently have been found to have cognitive-enhancing and neuroprotective effects in rodents (Prickaerts et al. [@CR31]; Zhang et al. [@CR43]). PDE5 has been identified in rat brain, including the cortex and hippocampus (van Staveren et al. [@CR40]; Van Staveren et al. [@CR39]), and subchronic administration of sildenafil has been demonstrated to increase cortical cGMP levels (Prickaerts et al. [@CR30]; Zhang et al. [@CR43]).

Intrahippocampal administration of an inhibitor of guanylate cyclase (to selectively lower cGMP concentrations) impaired learning of inhibitory avoidance in rats (Bernabeu et al. [@CR7]), whereas administration of an analog of cGMP facilitated memory consolidation (Bernabeu et al. [@CR8]). Sildenafil 3 and 10 mg/kg. significantly improved retention at 24 h of an object recognition task in rats (Prickaerts et al. [@CR30]), and sildenafil 3 mg/kg improved retention at 48 h of a passive avoidance task utilizing an aversive stimulus (Baratti and Boccia [@CR3]). Sildenafil 2, 4, and 8 mg/kg also dose-dependently improved acquisition of maze learning in mice (Singh and Parle [@CR36]). Sildenafil reversed cognitive deficits in rats produced by electroconvulsive therapy (Patil et al. [@CR28]), diabetes (Patil et al. [@CR28]), anticholinergics (Devan et al. [@CR14]), hyperammonemia (Erceg et al. [@CR18]), and NOS inhibitors (Devan et al. [@CR15], [@CR16]). Memory enhancement occurred when sildenafil was administered before training or up to 3 h post-training; administration immediately after training required the lowest dose, suggesting a primary effect on early memory consolidation rather than acquisition (Prickaerts et al. [@CR31], [@CR32]). In a placebo-controlled trial in healthy young men, sildenafil 100 mg significantly affected patterns of event-related potentials consistent with enhanced ability to focus attention and to select relevant target stimuli, although actual performance did not significantly improve (Schultheiss et al. [@CR35]). Sildenafil was safe and effective when administered to male schizophrenia patients for erectile dysfunction in two studies (Aviv et al. [@CR2]; Gopalakrishnan et al. [@CR22]).

We conducted a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 and 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor improves cognitive functioning and clinical symptoms.

Materials and methods {#Sec2}
=====================

Subjects were adult outpatients with schizophrenia recruited from a community mental health center and were clinically stable without a medication change for at least 4 weeks. Subjects had to be English speaking, be medically stable without cardiac disease, and free of substance abuse or dependence for at least 3 months. Patients were excluded if they were currently taking drugs that inhibit or induce hepatic cytochrome P450 3A4, nitrates, alpha blockers, or PDE5 inhibitors. Subjects could not be pregnant or have a history of priapism or inappropriate sexual behavior.

After providing written informed consent, patients met with a research psychiatrist to verify the diagnosis of schizophrenia by Diagnostic and Statistical Manual of Mental Disorders IV criteria and to review the medical history. A physical examination and vital signs were performed, and an electrocardiogram was obtained. Women of reproductive age were given a pregnancy test and counseled regarding use of appropriate birth control methods.

After the diagnosis had been confirmed and the patient had been medically cleared by the research psychiatrist, patients were scheduled for three sessions separated by 2 days. The order of study drug (sildenafil 50 mg, 100 mg, or placebo) was randomly assigned in a 1:1:1 ratio. Placebo and sildenafil were administered in identical-appearing capsules. Subjects continued to take all psychiatric medications without change during the course of the study. At baseline, the brief psychiatric rating scale (BPRS) was completed, and the cognitive battery was administered. In order to test memory consolidation, subjects returned 2 days later and were tested for a 48-h delayed recall of the Hopkins verbal learning test (HVLT) and logical memory test (LMT) that had been administered as part of the cognitive battery 2 days earlier. After blood pressure and pulse (sitting and standing) were measured, subjects were administered a single oral dose of the study drug. Starting 1 h after ingestion of the study drug, blood pressure, pulse, and self-reported side effects were recorded. The BPRS and cognitive battery were then repeated. Blood pressure and pulse were recorded again 2 h after administration of the study drug. Subjects completed three identical postbaseline sessions and returned 48 h after each session for testing of delayed recall.

The cognitive battery assessed five cognitive domains and included the following tests: the HVLT (Benedict et al. [@CR5]) using counterbalanced word lists to assess verbal learning, Letter--Number Sequencing (Wechsler Adult Intelligence Scale \[WAIS\]-III, The Psychological Corporation) and Digit Symbol (WAIS-III, The Psychological Corporation) to assess processing speed, category fluency to assess semantic fluency (Benton and Hamsher [@CR6]), the continuous performance test---identical pairs to assess attention and vigilance, and Spatial Span (Wechsler Memory Scale III) to assess spatial memory. A summary score was derived for each test using the standardized *z* score for the single item or mean for that test rectified so that a positive change in *z* score represents improved performance. A composite cognitive score was calculated from the mean of these five *z* scores. In addition, to assess memory consolidation, recall was tested after a 48-h delay following administration of the HVLT to test verbal memory and the LMT (story A) from the Revised Wechsler Memory Scale (Wechsler [@CR41]) to test verbal thematic recall.

Statistical analysis {#Sec3}
====================

The analysis was based on intent-to-treat and included all 17 randomized subjects. Differences in baseline and demographic variables were assessed using Student's *t* test and Chi-square or Fisher's exact test. The primary outcome measure was change in composite cognitive score from baseline. Secondary outcome measures included change from baseline in each of the five cognitive domains, BPRS total, BPRS negative symptom subscale, BPRS depression item, and 48-h delayed performance on the HVLT and LMT. For these variables, analysis of covariance were performed to determine differences between placebo, sildenafil 50 and 100 mg, controlling for order (PROC GLM). All analyses were performed using SAS. An alpha of 0.05 was used to determine significance, and because of the exploratory nature of this study, a correction was not made for multiple comparisons.

Results {#Sec4}
=======

Eighteen patients were enrolled, 17 were randomized, and 15 completed all three treatment conditions. One subject dropped out after the first treatment session (placebo), and one was dropped from study 2 days after the first treatment session (sildenafil 100 mg) due to irritability; this patient was subsequently hospitalized. The mean age of completers was 49.7 years (SD = 0.6). Eight subjects (47%) were male. Twelve of the 17 subjects (71%) were Caucasian, four subjects (24%) were African-American, and one subject (6%) was Hispanic. Five subjects were treated with olanzapine, two with clozapine, two with aripiprazole, two with conventional antipsychotics, two with risperidone, one with quetiapine, and three with combination (quetiapine and fluphenazine, olanzapine and ziprasidone, and perphenazine and ziprasidone).

There was no significant main effect of study medication on change in composite cognitive score from baseline. Additionally, a main effect of study medication was not found for any of the secondary outcome measures. Effect sizes of study drug for cognitive domains ranged from 0.07 (small) to 0.61 (large), and in each comparison, performance improved more (or worsened less) with placebo compared to sildenafil. Effect sizes for the Positive and Negative Syndrome Scale (PANSS) total and PANSS subscale scores were all small (0.00--0.21) and also favored placebo.

Side effects {#Sec5}
============

Sildenafil was generally well tolerated, although one dropout due to irritability occurred following administration of sildenafil 100 mg. One subject reported moderate sedation 1 h after the sildenafil 100-mg dose. Two subjects exhibited drops in diastolic blood pressure of 7 and 14 mmHg after sildenafil 100 mg; in both cases, the systolic blood pressure did not drop, and the subject remained asymptomatic. Reports of dizziness were not more common with sildenafil compared to placebo, and no headaches or visual disturbances were reported (Table [1](#Tab1){ref-type="table"}). Table 1Mean change scores from baseline to poststudy drug administration PlaceboSildenafil 50 mgESSildenafil 100 mgES*F* value*p* valueSymptomsBPRS^a^Positive symptom total0.06 ± 0.250.40 ± 1.300.210.06 ± 0.250.000.010.99Negative symptom total−0.15 ± 0.54−0.16 ± 0.670.02−0.08 ± 0.710.140.080.93Depression item−0.06 ± 0.250.00 ± 0.000.060.00 ± 0.000.060.040.96Total−0.19 ± 1.22−0.20 ± 0.560.00−0.06 ± 0.570.030.300.74Cognitive tests^b^HVLTTotal recall−0.50 ± 5.05−0.87 ± 4.000.08−1.50 ± 4.580.220.190.83Delayed (48 h) recall−1.53 ± 2.45−1.27 ± 1.980.11−2.07 ± 2.550.230.440.64Letter numberWithout reordering0.56 ± 1.860.47 ± 1.190.050.44 ± 1.750.070.020.98With reordering0.13 ± 1.54−0.40 ± 1.680.33^c^0.00 ± 1.550.080.450.64Digit symbol total7.19 ± 8.423.20 ± 7.050.49^c^5.63 ± 9.060.190.930.40Animals: total3.69 ± 3.652.60 ± 3.270.31^c^3.00 ± 3.460.200.390.68CPT−IP2 d′0.24 ± 0.690.05 ± 0.860.260.02 ± 0.620.30^c^0.380.683 d′0.25 ± 0.830.34 ± 0.920.110.26 ± 0.810.010.040.964 d′0.50 ± 0.570.18 ± 0.670.54^c^0.28 ± 0.530.37^c^1.110.34Spatial spanForward−0.06 ± 1.69−0.14 ± 1.230.05−0.38 ± 1.630.210.170.84Reverse0.94 ± 1.650.57 ± 1.740.220.63 ± 1.630.190.220.80Logical memory---thematicImmediate0.94 ± 1.120.80 ± 1.780.100.81 ± 1.330.090.050.95Delayed (48 h)2.27 ± 1.711.80 ± 1.900.292.20 ± 1.610.040.360.70Logical memory---unitImmediate3.56 ± 2.852.87 ± 3.830.223.38 ± 3.260.060.210.81Delayed (48 h)6.13 ± 4.605.80 ± 5.620.076.33 ± 5.340.040.050.95Cognitive domains (*z* scores)^b^Verbal memory−0.01 ± 1.06−0.08 ± 0.840.07−0.22 ± 0.970.220.190.83Working memory−0.05 ± 0.30−0.23 ± 0.230.61^d^−0.12 ± 0.340.241.470.24Semantic fluency0.02 ± 0.61−0.18 ± 0.580.34^c^−0.10 ± 0.610.200.460.63Attention0.06 ± 0.43−0.12 ± 0.490.38^c^−0.12 ± 0.510.38^c^0.710.50Spatial memory−0.01 ± 0.68−0.11 ± 0.460.17−0.15 ± 0.530.240.250.78Cognitive composite (*z* scores)0.00 ± 0.32−0.13 ± 0.330.40^c^−0.14 ± 0.330.43^c^0.950.39^a^Positive change from baseline reflects worsening/negative change from baseline reflects improvement in measure^b^Positive change from baseline reflects improvement/negative change from baseline reflects worsening in measure^c^Medium effect size^d^Large effect size

Discussion {#Sec6}
==========

Our hypothesis, that sildenafil would improve cognition when added to antipsychotics in patients with schizophrenia, was not supported. The explanation for this negative finding is uncertain. It is possible that the potential effect is too small to detect in a sample of this size. It is also possible that both doses of sildenafil administered in this study were outside an effective dose range. Studies in rats have identified an inverted U-shaped dose--response relationship with an optimal dose of 1--10 mg/kg. In an object recognition task in rats, sildenafil improved memory when administered at a dose of 3 mg/kg immediately after training, whereas a dose of 10 mg/kg was required when administered 30 min prior to training. The increase in minimum effective dose was attributed to the rapid metabolism of sildenafil (half-life of 0.4 h) necessitating a higher dose to achieve adequate brain concentrations during the period of cGMP-dependent memory consolidation (Prickaerts et al. [@CR31]). The half-life of sildenafil in humans is 4 h, suggesting that administration 1 h prior to cognitive testing should not be complicated by the rapid clearance observed in rats (Boolell et al. [@CR10]). Because sildenafil readily crosses the blood--brain barrier, the doses administered in this study would be expected to substantially inhibit brain PDE5. It is possible that repeated dosing may be required to produce cognitive or behavioral effects. In animal studies, cognitive effects have been demonstrated with both single and repeated dosing. Daily dosing with sildenafil has not been studied in schizophrenia, although this approach has been utilized successfully in the treatment of pulmonary hypertension (Chockalingam et al. [@CR12]).

Sildenafil was generally well tolerated, although one subject experienced irritability following sildenafil 100 mg. While it is unclear whether this dysphoric response resulted from study drug, rare reports of central nervous system adverse effects have been reported, including aggression and amnesia (Milman and Arnold [@CR24]). In addition, increased aggression was observed in mice 1 week after discontinuation of a 4-week regimen of high-dose sildenafil administered three times weekly (Hotchkiss et al. [@CR23]). However, no worsening of psychiatric symptom ratings was observed in a 6-week open trial of sildenafil 25--75 mg administered as needed to 12 schizophrenia patients with erectile dysfunction (Aviv et al. [@CR2]).

A large literature has implicated dysregulation of neuronal NOS in schizophrenia (Bernstein et al. [@CR9]). Evidence suggesting abnormalities in this intermediate step of the NMDA/NO/cGMP pathway include linkage of the carboxyl-terminal PDZ-ligand of nNos (CAPON) to schizophrenia (Eastwood [@CR17]), altered concentrations of NO and NO metabolites in blood and cerebrospinal fluid, and, in postmortem brain, abnormalities in the cortical distribution of neuronal NOS (nNOS)-expressing neurons (Akbarian et al. [@CR1]), nNOS ribonucleic acid expression, and nNOS activity (Bernstein et al. [@CR9]). However, the complexity of findings makes it difficult to predict whether dysregulation of NO is primarily in the direction of an increase or decrease. In addition, haloperidol and chlorpromazine but not second-generation antipsychotics, decrease nNOS activity in rats (Nel and Harvey [@CR25]; Tarazi et al. [@CR37]). Deutsch et al. ([@CR13]) reported an improvement in psychopathology ratings with the NOS inhibitor, methylene blue, in a pilot study of eight antipsychotic-refractory schizophrenia patients.

Whereas evidence for dysregulation of nNOS in schizophrenia supports pharmacological targeting of the NMDA/NO/cGMP pathway, it is possible that an underlying impairment of function in this pathway could result in reduced or absent cognitive enhancement with PDE5 inhibition. PDE5 inhibition amplifies the signal generated by NMDA receptor activation and NO release; cGMP levels will not increase if this pathway is not intact. Studies in healthy, medication-free subjects are needed to assess whether the encouraging findings of cognitive enhancement in animal models can be translated to humans. The one published study of sildenafil in healthy subjects produced ambiguous results; electrophysiologic measures of concentration improved, whereas performance did not (Schultheiss et al. [@CR35]). In addition, inhibitors of other subtypes of PDE may be more effective in producing cognitive effects in humans. PDE4 inhibitors are currently being developed for cognitive disorders, and PDE10 inhibitors are under study for the treatment of schizophrenia (Bender and Beavo [@CR4]).

Conclusion {#Sec7}
==========

Despite an animal literature demonstrating cognitive-enhancing effects of sildenafil and a rationale for sildenafil as a strategy for facilitating NMDA receptor-mediated effects on memory by targeting intracellular pathways downstream from NMDA receptors, we did not detect effects of a single dose of sildenafil 50 and 100 mg on a traditional cognitive battery, nor did we find evidence for improved memory consolidation when recall was tested after 48 h. Symptoms of schizophrenia also did not improve. It is possible that the doses used in this study were not optimal, that repeated dosing may be necessary to achieve therapeutic effects, or that PDE5 inhibition is not a viable strategy in medicated schizophrenia patients. Additional studies of alternative dosing strategies in healthy subjects may provide some clarification. Agents under development that inhibit other subtypes of PDE remain promising.
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